{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:19:00Z","timestamp":1773299940298,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.hoc.2021.02.003","type":"journal-article","created":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T18:48:03Z","timestamp":1618771683000},"page":"513-529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Current Therapy and Emerging Intravesical Agents to Treat Non\u2013Muscle Invasive Bladder Cancer"],"prefix":"10.1016","volume":"35","author":[{"given":"Kelly K.","family":"Bree","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan A.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2021.02.003_bib1","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2021.02.003_bib2","first-page":"1","article-title":"Primary Ta high grade bladder tumors: determination of the risk of progression","volume":"00","author":"Quhal","year":"2020","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2021.02.003_bib3","first-page":"1021","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.hoc.2021.02.003_bib4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non-muscle invasive bladder cancer (Ta T1 and carcinoma in\u00a0situ): 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.hoc.2021.02.003_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.hoc.2021.02.003_bib6","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2021.02.003_bib7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.eururo.2017.06.038","article-title":"Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicenter randomized study of 2243 patients","volume":"73","author":"Bosschiter","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.hoc.2021.02.003_bib8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","article-title":"Should all patients with non\u2013muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study","volume":"55","author":"Gudj\u00f3nsson","year":"2009","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.hoc.2021.02.003_bib9","first-page":"305","article-title":"Defining and treating the spectrum of intermediate-risk NMIBC","volume":"192","author":"Kamat","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.hoc.2021.02.003_bib10","series-title":"Emerging approaches to diagnosis and treatment of non\u2013muscle-invasive bladder cancer [Internet]","author":"Chou","year":"2015"},{"key":"10.1016\/j.hoc.2021.02.003_bib11","first-page":"CD009294","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"1","author":"Jones","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.hoc.2021.02.003_bib12","first-page":"180","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.hoc.2021.02.003_bib13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.hoc.2021.02.003_bib14","first-page":"1964","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.hoc.2021.02.003_bib15","first-page":"1124","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1, and carcinoma in\u00a0situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.hoc.2021.02.003_bib16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette\u2013Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.hoc.2021.02.003_bib17","first-page":"86","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in\u00a0situ of the bladder; a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.hoc.2021.02.003_bib18","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.hoc.2021.02.003_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5489\/cuaj.10040","article-title":"Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience","volume":"5","author":"Chalasani","year":"2011","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.hoc.2021.02.003_bib20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","article-title":"Management of BCG failures in superficial bladder cancer: a review","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.hoc.2021.02.003_bib21","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.clgc.2017.07.011","article-title":"Utilization and outcomes of radical cystectomy for high-grade non\u2013muscle-invasive bladder cancer in elderly patients","volume":"16","author":"Parker","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.hoc.2021.02.003_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.euo.2020.02.006","article-title":"Evidence-based assessment of current and emerging bladder-sparing therapies for non\u2013muscle-invasive bladder cancer after bacillus Calmette-Guerin therapy: a systematic review and meta-analysis","volume":"3","author":"Kamat","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2021.02.003_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4103\/0970-1591.166475","article-title":"Treatment options in non-muscle-invasive bladder cancer after BCG failure","volume":"31","author":"Brooks","year":"2015","journal-title":"Indian J Urol"},{"issue":"3","key":"10.1016\/j.hoc.2021.02.003_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MOU.0000000000000593","article-title":"Salvage therapeutic strategies for bacillus Calmette\u2013Guerin failure","volume":"29","author":"Hassler","year":"2019","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.hoc.2021.02.003_bib25","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.eururo.2012.08.055","article-title":"Treatment options available for bacillus Calmette-Gu\u00e9rin failure in non\u2013muscle-invasive bladder cancer","volume":"62","author":"Yates","year":"2012","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.hoc.2021.02.003_bib26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.hoc.2021.02.003_bib27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/BLC-160053","article-title":"Summary and recommendations from the National Cancer Institute\u2019s clinical trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer","volume":"2","author":"Lerner","year":"2016","journal-title":"Bladder Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2021.02.003_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2018.09.028","article-title":"Prognostic implication of the United States Food and Drug Administration-defined BCG-unresponsive disease","volume":"75","author":"Li","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.hoc.2021.02.003_bib29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0090-4295(96)00621-8","article-title":"Initial report on intravesical administration of N-trifluoroacetyladreiamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder","volume":"49","author":"Greenberg","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.hoc.2021.02.003_bib30","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in\u00a0situ and contraindication to or failure after bacillus Calmette-Guerin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2021.02.003_bib31","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"issue":"supplemental 15","key":"10.1016\/j.hoc.2021.02.003_bib32","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1200\/JCO.2020.38.15_suppl.5041","article-title":"Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Gu\u00e9rin (BCG) unresponsive, high-risk (HR) non\u2013muscle-invasive bladder cancer (NMIBC): over two years follow-up of KEYNOTE-057","volume":"38","author":"Balar","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2021.02.003_bib33","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00345-018-2553-7","article-title":"The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside","volume":"37","author":"Duplisea","year":"2019","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.hoc.2021.02.003_bib34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/JCO.2020.38.6_suppl.442","article-title":"Safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade, BCG unresponsive nonmuscle invasive bladder cancer (NMIBC): results from a phase III trial","volume":"38","author":"Boorjian","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"supplemental 4","key":"10.1016\/j.hoc.2021.02.003_bib35","first-page":"e261","article-title":"PD12-07: A phase III study to evaluate the safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade, BCG unresponsive non-muscle invasive bladder cancer: papillary disease cohort results","volume":"203","author":"Boorjian","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.hoc.2021.02.003_bib36","first-page":"902","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"supplemental 4","key":"10.1016\/j.hoc.2021.02.003_bib37","first-page":"e72","article-title":"PD03-02: phase 3 results of vicinium in BCG-unresponsive non-muscle invasive bladder cancer","volume":"203","author":"Shore","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"7","key":"10.1016\/j.hoc.2021.02.003_bib38","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.urolonc.2012.02.007","article-title":"Photodynamic therapy of bladder cancer: a phase I study using hexaminolevulinate (HAL)","volume":"31","author":"Bader","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.hoc.2021.02.003_bib39","first-page":"777","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.hoc.2021.02.003_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.hoc.2021.02.003_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","article-title":"Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models","volume":"4","author":"Rhode","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"supplemental 15","key":"10.1016\/j.hoc.2021.02.003_bib42","doi-asserted-by":"crossref","first-page":"TPS5090","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5090","article-title":"A\u00a0phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT","volume":"38","author":"Hahn","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2021.02.003_bib43","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2007.06.030","article-title":"Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?","volume":"53","author":"Denzinger","year":"2008","journal-title":"Eur Urol"},{"issue":"8 Pt 2","key":"10.1016\/j.hoc.2021.02.003_bib44","doi-asserted-by":"crossref","first-page":"E284","DOI":"10.1111\/j.1464-410X.2010.09980.x","article-title":"Early vs delayed radical cystectomy for \u2018high-risk\u2019 carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival","volume":"108","author":"J\u00e4ger","year":"2011","journal-title":"BJU Int"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858821000216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858821000216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:15:02Z","timestamp":1760184902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858821000216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0889858821000216"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2021.02.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Therapy and Emerging Intravesical Agents to Treat Non\u2013Muscle Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2021.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}